目的探讨美罗华联合传统方案治疗儿童CD20阳性非霍奇金淋巴瘤的疗效及毒副反应。方法传统化疗方案使用美国国立癌症研究所推荐的多中心协作方案(MCP),每次传统化疗前加用美罗华375mg/m2,1d,连续6个方案。结果治疗中无明显毒副作用,治疗后15个月临床无复发。结论美罗华可改善非霍奇金淋巴瘤患儿预后,且无毒副反应。 Objective To investigate the curative effect and toxicity of rituximab combined with traditional regimen in treating children with non-Hodgkin’s lymphoma (CD20). Methods The traditional chemotherapy regimen used the multicentre collaborative regimen (MCP) recommended by the National Cancer Institute, with 6 consecutive doses of rituximab 375 mg once daily prior to each conventional chemotherapy. Results no obvious side effects in the treatment, 15 months after treatment, no clinical recurrence. Conclusion Rituximab can improve the prognosis of children with non-Hodgkin’s lymphoma and has no toxic side effects.